SCHEMBL6350983

SCHEMBL6350983

CC(=O)N(CC(=O)c1ccccc1)C(CC(C)C)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
USP2 O75604 1/20 0.43
KMT2A Q03164 3/20 0.41
NR4A2 P43354 1/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 2/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
CES1 P23141 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
AGTR1 P30556 1/20 0.38
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
F7 P08709 1/20 0.37
LTA4H P09960 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350920 0.89 ALDH1A1 (0.41) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6345185 0.85 KDM4E (0.45) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL2333269 0.84 ALDH1A1 (0.44) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6360094 0.81 KDM4E (0.42) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6350103 0.79 ALDH1A1 (0.40) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6350978 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6349361 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6356051 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6350686 0.77 KDM4E (0.46) ALDH1A1KDM4EUSP2KMT2ANR4A2
SCHEMBL6351176 0.77 TRPM8 (0.44) ALDH1A1KDM4EUSP2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 ALDH1A1 420/4885KDM4E 2934/4885USP2 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.